{"entity":{"id":"nct06265688","kind":"trial","name":"First In Human Study of CX-2051 in Advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of Varsetatug masetecan run by CytomX Therapeutics, now recruiting.","summary":"First In Human Study of CX-2051 in Advanced Solid Tumors is a phase 1 interventional study registered as NCT06265688 by CytomX Therapeutics, with 160 participants planned, started 2024-04-02. Conditions recorded: Solid Tumor, Adult. Interventions recorded: CX-2051 and Bevacizumab.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06265688","url":"https://clinicaltrials.gov/study/NCT06265688"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["varsetatug-masetecan"],"companies":["cytomx-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06265688","phase":"1","setting":"An Investigational Study of CX-2051 in Participants With Advanced Solid Tumors","sponsor":"CytomX Therapeutics","enrolled":160,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06265688/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"varsetatug-masetecan","kind":"drug","name":"Varsetatug masetecan","route":"/drugs/varsetatug-masetecan/"}],"company":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"}]}}